TY - JOUR
T1 - International consensus statement on diagnosis, evaluation, and research of Richter transformation
T2 - the ERIC recommendations
AU - Kittai, Adam S.
AU - Marchetti, Monia
AU - Al-Sawaf, Othman
AU - Benjamini, Ohad
AU - Danilov, Alexey V.
AU - Davids, Matthew S.
AU - Eichhorst, Barbara
AU - Eyre, Toby A.
AU - Frustaci, Anna Maria
AU - Hallek, Michael
AU - Hampel, Paul J.
AU - Herishanu, Yair
AU - Hicks, Rodney J.
AU - Kater, Arnon P.
AU - King, Rebecca L.
AU - Martin-Subero, Jose I.
AU - Owen, Carolyn
AU - Parry, Erin
AU - Ponzoni, Maurilio
AU - Rossi, Davide
AU - Siddiqi, Tanya
AU - Stilgenbauer, Stephan
AU - Tam, Constantine S.
AU - Hacken, Elisa ten
AU - Thompson, Philip A.
AU - Wierda, William
AU - Gaidano, Gianluca
AU - Woyach, Jennifer A.
AU - Ghia, Paolo
N1 - Publisher Copyright:
© 2025 American Society of Hematology
PY - 2025/7/17
Y1 - 2025/7/17
N2 - Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography–computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.
AB - Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography–computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.
UR - https://www.scopus.com/pages/publications/105005498361
U2 - 10.1182/blood.2024028064
DO - 10.1182/blood.2024028064
M3 - Comment/debate
SN - 0006-4971
VL - 146
SP - 291
EP - 303
JO - Blood
JF - Blood
IS - 3
ER -